Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in OncologyMary B. Daly, Mary A. Dwyer, Tuya Pal et al.|Journal of the National Comprehensive Cancer Network|2021Cited by 1.1k
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017Mary B. Daly, Susan Darlow, Susan Friedman et al.|Journal of the National Comprehensive Cancer Network|2016Cited by 660
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020Mary B. Daly, Susan Darlow, Robert Pilarski et al.|Journal of the National Comprehensive Cancer Network|2020Cited by 507
Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in OncologyJohn A. Thompson, Lisa Hang, Bryan J. Schneider et al.|Journal of the National Comprehensive Cancer Network|2022Cited by 416
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 2.2019Samir Gupta, Ndiya Ogba, Dawn Provenzale et al.|Journal of the National Comprehensive Cancer Network|2019Cited by 342